drugset
drugset / Trial / NCT05235269

A Study to Evaluate Organ Level Uptake Repeatability of 124I AT-01 in Subjects With Systemic Amyloidosis

NCT05235269 ↗

Phase 2 Completed 33 enrolled Attralus, Inc.
NaSingle-groupOpen-labelDiagnostic

Summary

This study is designed to assess the repeatability of organ-specific quantitation of radiotracer uptake following Positron Emission Tomography/Computed Tomography (PET/CT) imaging of AT- 01 in subjects with amyloid light chain (AL) or amyloid transthyretin (ATTR) systemic amyloidosis.

Timeline

Start
2021-11-30
Primary completion
2023-02-06
Completion
2023-02-24

Drugs

EvaluationDrugModalityDoseRoute
Subject IODINE I124 EVUZAMITIDE Diagnostic / imaging agent 37 mbq Intravenous

Indications

amyloidosis